Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial.

Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial. Gut. 2019 Feb 01;: Authors: de Groof EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, Bosmans JE, van Dongen JM, Mol B, Buskens CJ, Stokkers PCF, Hart A, D’Haens GR, Bemelman WA, Ponsioen CY, LIR!C study group Abstract OBJECTIVE: Evaluate the cost-effectiveness of laparoscopic ileocaecal resection compared with infliximab in patients with ileocaecal Crohn’s disease failing conventional therapy. DESIGN: A multicentre randomised controlled trial was performed in 29 centres in The Netherlands and the…

Read More

Should we resect the mesentery in ileocolic Crohn’s disease ? – A response to “A warning about the role of extended mesenteric resection in Crohn’s disease recurrence”.

Should we resect the mesentery in ileocolic Crohn’s disease ? – A response to “A warning about the role of extended mesenteric resection in Crohn’s disease recurrence”. J Crohns Colitis. 2019 Jun 17;: Authors: Fleming C, Mohan H, Coffey JC PMID: 31211834 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31211834?dopt=Abstract

Read More

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.

Related Articles Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2019 Jun 12;: Authors: Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M Abstract OBJECTIVES: To better understand the real-world impact of biologic therapy in persons with Crohn’s disease (CD) and UC, we evaluated the effect of marketplace introduction of infliximab on the population rates of hospitalisations and surgeries and public payer drug…

Read More

Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn’s disease: results from the Porto Group GROWTH study.

Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn’s disease: results from the Porto Group GROWTH study. J Crohns Colitis. 2019 Jun 03;: Authors: Levine A, Chanchlani N, Ziv-Baran T, Escher JC, Amil Dias J, Veres G, Koletzko S, Turner D, Kolho KL, Paerregaard A, Staiano A, Lionetti P, Nuti F, Sladek M, Shaoul R, Lazowska-Prezeorek I, de Carpi JM, Sigall Boneh R, Pfeffer Gik T, Cohen-Dolev N, Russell RK, Porto Group of ESPGHAN Abstract INTRODUCTION: The ability to predict risk for poor outcomes in Crohn’s…

Read More

Postoperative morbidity after iterative ileocolonic resection for Crohn’s Disease: should we be worried? A prospective multicentric cohort study of the GETAID Chirurgie.

Related Articles Postoperative morbidity after iterative ileocolonic resection for Crohn’s Disease: should we be worried? A prospective multicentric cohort study of the GETAID Chirurgie. J Crohns Colitis. 2019 May 04;: Authors: Abdalla S, Brouquet A, Maggiori L, Zerbib P, Denost Q, Germain A, Cotte E, Beyer-Berjot L, Munoz-Bongrand N, Desfourneaux V, Rahili A, Duffas JP, Pautrat K, Denet C, Bridoux V, Meurette G, Faucheron JL, Loriau J, Guillon F, Vicaut E, Benoist S, Panis Y, Lefevre JH, GETAID chirurgie group Abstract BACKGROUND AND AIMS: To compare perioperative characteristics and outcomes…

Read More

Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn’s Disease.

Related Articles Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Apr 28;: Authors: Hammoudi N, Cazals-Hatem D, Auzolle C, Gardair C, Ngollo M, Bottois H, Nancey S, Pariente B, Buisson A, Treton X, Fumery M, Bezault M, Seksik P, Le Bourhis L, REMIND study group investigators, Flejou JF, Allez M Abstract BACKGROUND AND AIMS: Different types of histologic lesions at the ileal margin, detected by histology, have been associated with increased rates of recurrence after ileocaecal surgery…

Read More

Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study.

Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study. J Crohns Colitis. 2019 Apr 17;: Authors: Al-Kandari A, Thayalasekaran S, Bhandari M, Przybysz A, Bugajski M, Bassett P, Kandiah K, Subramaniam S, Galtieri P, Maselli R, Spychalski M, Hayee B, Haji A, Repici A, Kaminski M, Bhandari P Abstract BACKGROUND: Inflammatory bowel disease is associated with an increased risk of colorectal cancer, with estimates ranging from 2-18%, depending on the duration of colitis. The management of neoplasia in colitis remains controversial. Current guidelines recommend endoscopic resection if the…

Read More

Ultrasound vs Endoscopy, Surgery, or Pathology for the Diagnosis of Small Bowel Crohn’s Disease and its Complications.

Ultrasound vs Endoscopy, Surgery, or Pathology for the Diagnosis of Small Bowel Crohn’s Disease and its Complications. Inflamm Bowel Dis. 2019 Mar 19;: Authors: Bollegala N, Griller N, Bannerman H, Habal M, Nguyen GC Abstract BACKGROUND: In patients with inflammatory bowel disease, we strive to achieve mucosal healing, as this has been shown to decrease the risk of disease flares, hospitalization, and surgery. For this reason, we must use objective measures of mucosal healing to inform our clinical decision-making and can no longer rely on patient symptoms alone. Assessment of…

Read More

Ileal Gene Expression Data from Crohn’s Disease Small Bowel Resections Indicate Distinct Clinical Sub-Groups.

Related Articles Ileal Gene Expression Data from Crohn’s Disease Small Bowel Resections Indicate Distinct Clinical Sub-Groups. J Crohns Colitis. 2019 Mar 16;: Authors: Potdar AA, Li D, Haritunians T, VanDussen KL, Fiorino MF, Liu TC, Stappenbeck TS, Fleshner P, Targan SR, McGovern DPB, Bilsborough J Abstract BACKGROUND AND AIMS: Heterogeneity in Crohn’s disease (CD) provides a challenge for development of effective therapies. Our goal was to define a unique molecular signature for severe, refractory CD to enable precision therapy approaches to disease treatment and facilitate earlier intervention in complicated disease.…

Read More
<< Go Back